Overview

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of ABT-869 plus paclitaxel compared to paclitaxel alone on disease progression in metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborator:
Genentech, Inc.
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel